Keyphrases
Metastatic Colorectal Cancer (mCRC)
100%
C-reactive Protein
100%
Carcinoembryonic Antigen
100%
Total Cell-free DNA
100%
Confidence Interval
57%
Overall Survival
57%
Cell-free DNA (cfDNA)
42%
Prognostic Value
42%
Progression-free Survival
28%
Patient Prognosis
28%
Clinical Decision-making
14%
DNA Quantification
14%
Everolimus
14%
Irinotecan
14%
Plasma Samples
14%
Heavily Pretreated Patients
14%
High Risk
14%
Treatment Decisions
14%
Multivariate Analysis
14%
Droplet Digital PCR (ddPCR)
14%
Risk Profile
14%
Phase II Clinical Trial
14%
Cox Regression
14%
Blood Samples
14%
Shared Decision Making
14%
Cetuximab
14%
Upper Normal Limit
14%
Clinical Endpoints
14%
Plasma Parameters
14%
Patient Assessment
14%
Median Overall Survival
14%
DNA Purification
14%
Medicine and Dentistry
Cell-Free DNA
100%
Carcinoembryonic Antigen
100%
C Reactive Protein
100%
Metastatic Colorectal Cancer
100%
Overall Survival
50%
Progression Free Survival
20%
Multivariate Analysis
10%
Clinical Decision Making
10%
Irinotecan
10%
Shared Decision Making
10%
Proportional Hazards Model
10%
Droplet Digital Polymerase Chain Reaction
10%
Clinical Endpoint
10%
Clinical Trial
10%
Allele
10%
Everolimus
10%
Cetuximab
10%
Copurification
10%
Biochemistry, Genetics and Molecular Biology
C-Reactive Protein
100%
Carcinoembryonic Antigen
100%
Overall Survival
83%
Blood Plasma
50%
Progression Free Survival
33%
Clinical Decision Making
16%
Blood Level
16%
Droplet Digital Polymerase Chain Reaction
16%
Clinical Trial
16%
Multivariate Analysis
16%
Shared Decision Making
16%
Allele
16%
DNA Purification
16%
Cetuximab
16%
Pharmacology, Toxicology and Pharmaceutical Science
C Reactive Protein
100%
Carcinoembryonic Antigen
100%
Metastatic Colorectal Cancer
100%
Overall Survival
83%
Progression Free Survival
33%
Everolimus
16%
Cetuximab
16%
Clinical Trial
16%
Irinotecan
16%